Physician profile
Gary Seward
NPI 1154365245
$991.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $163.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.34 | 2019-2020 | |
| Novo Nordisk INC | $138.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $81.27 | 2019-2020 | |
| Lilly USA, LLC | $70.77 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $59.85 | 2019-2020 | |
| Pfizer INC. | $40.54 | 2019 | |
| Merck Sharp & Dohme LLC | $38.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.48 | 2019-2020 | |
| Vifor Pharma, INC. | $27.32 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.59 | 2019 | |
| Dynavax Technologies Corporation | $20.11 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.86 | 2019 | |
| Amarin Pharma, INC. | $16.96 | 2019 | |
| Boston Scientific Corporation | $15.87 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.